 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | RX-af01 - Sun Yat / sen University
Enrollment change, Trial completion date, Trial primary completion date, Metastases: Safety and Efficacy of RX-af01 Combined With PD-1 Antibody (clinicaltrials.gov) - Jan 23, 2024
P1/2, N=60, Recruiting, Sponsor: Sun Yat-sen University
N=14 --> 60 | Trial completion date: Sep 2023 --> Dec 2024 | Trial primary completion date: Sep 2023 --> Dec 2024
- | RX-af01 - Sun Yat / sen University
New P1/2 trial, Metastases: Safety and Efficacy of RX-af01 Combined With PD-1 Antibody (clinicaltrials.gov) - Oct 13, 2022
P1/2, N=14, Recruiting, Sponsor: Sun Yat-sen University